Published in Hospital Business Week, July 19th, 2009
"Symptoms improved within 1 week. No relapses were observed," wrote B.L. Herpers and colleagues, St. Antonius Hospital.
The researchers concluded: "This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI."
Herpers and colleagues published the results of their research in Clinical Infectious Diseases (Intravenous Tigecycline as Adjunctive or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.